RIGEL PHARMACEUTICALS INC (RIGL)
About RIGEL PHARMACEUTICALS INC
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $294.3M
- Net income
- $367.0M
- Total assets
- $513.6M
- Market cap
- $553.8M
- Gross margin
- 93.3%
- Operating margin
- 42.6%
- Net margin
- 124.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $294.3M
- Cost of revenue
- $19.6M
- Gross profit
- $274.7M
- Operating expenses
- $149.2M
- Operating income
- $125.5M
- Income tax
- -$245.2M
- Net income
- $367.0M
- EPS (basic)
- $20.40
- EPS (diluted)
- $19.48
Balance sheet
- Total assets
- $513.6M
- Current assets
- $240.2M
- Total liabilities
- $122.1M
- Current liabilities
- $99.2M
- Shareholders’ equity
- $391.5M
Cash flow
- Operating cash flow
- $75.7M
- Investing cash flow
- -$92.4M
- Financing cash flow
- $601.0K
- Net cash flow
- -$16.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $553.8M
- P/E ratio
- 1.9
- EPS (diluted)
- $19.48
- Shares outstanding
- 15.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 29, 2000
Rigel Pharmaceuticals Inc (RIGL) Stock Price
- Profitable — net income of $367.0M in FY2025.
- Revenue grew 97% from FY2021 to FY2025.
- Gross margin of 93.3%, net margin 124.7%.
- Trading 28% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 1.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review RIGEL PHARMACEUTICALS INC.
Write a review
News about RIGEL PHARMACEUTICALS INC
News & sentiment via Polygon.io
Rigel Pharmaceuticals Inc: frequently asked questions
Is Rigel Pharmaceuticals Inc an American company?
Rigel Pharmaceuticals Inc is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Rigel Pharmaceuticals Inc headquartered?
Rigel Pharmaceuticals Inc is headquartered in South San Francisco, California, United States.
Is Rigel Pharmaceuticals Inc publicly traded?
Yes — Rigel Pharmaceuticals Inc is a publicly traded company. Its stock trades under the ticker symbol RIGL on the NASDAQ.
What does Rigel Pharmaceuticals Inc do?
Rigel Pharmaceuticals Inc is an American Pharmaceuticals company in the Health & Beauty sector.
